CORRESP Filing
Lyell Immunopharma, Inc.
Date: July 28, 2025 · CIK: 0001806952 · Accession: 0001193125-25-166426
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-288769
Letter
RE: Lyell Immunopharma, Inc . (the “ Company ”) Registration Statement on Form S-3 File No. 333-288769 Dear Mr. Campbell: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-288769) be accelerated by the Securities and Exchange Commission to 4:00 p.m. New York time on July 30, 2025, or as soon as practicable thereafter. We request that we be notified of such effectiveness by a telephone call to Thomas W. Greenberg of Skadden, Arps, Slate, Meagher & Flom LLP at (212) 735-7886 and that such effectiveness also be confirmed in writing.
LYELL IMMUNOPHARMA, INC. 201 Haskins Way South San Francisco, California 94080 (650) 695-0677 July 28, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attn: Alan Campbell
Very truly yours,
Lyell Immunopharma, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP LYELL IMMUNOPHARMA, INC. 201 Haskins Way South San Francisco, California 94080 (650) 695-0677 July 28, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attn: Alan Campbell RE: Lyell Immunopharma, Inc . (the “ Company ”) Registration Statement on Form S-3 File No. 333-288769 Dear Mr. Campbell: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-288769) be accelerated by the Securities and Exchange Commission to 4:00 p.m. New York time on July 30, 2025, or as soon as practicable thereafter. We request that we be notified of such effectiveness by a telephone call to Thomas W. Greenberg of Skadden, Arps, Slate, Meagher & Flom LLP at (212) 735-7886 and that such effectiveness also be confirmed in writing. Very truly yours, Lyell Immunopharma, Inc. By: /s/ Mark Meltz Mark Meltz General Counsel and Corporate Secretary cc: Thomas W. Greenberg Skadden, Arps, Slate, Meagher & Flom LLP